BUZZ—Neurocrine’s stock price rises after the company raised its 2026 sales forecast for its movement disorder drug

November 2 - ** Neurocrine Biosciences (NBIX.O) shares rose 6.9% in after-hours trading to $155.38

** NBIX raised its annual net product sales guidance range for its movement disorder drug Ingrezza from the previous $2.825 billion–$2.875 billion to $2.9 billion–$2.925 billion

** Third-quarter revenue was $1.12 billion, above analysts’ expectations of $1.04 billion—according to LSEG data

** The report showed quarterly sales of Ingrezza grew 17% year-on-year to $801 million

** RBC said the overall results beat expectations, indicating “the company’s recent promotional efforts may be starting to pay off”

** As of last session’s close, the stock is up 2.5% year-to-date

(To facilitate non-English speakers, Reuters has automated the translation of its reporting into several other languages. As automated translation may contain errors or lack necessary context, Reuters does not guarantee the accuracy of automated translation texts and provides them for readers’ convenience only. Reuters accepts no liability for any damage or loss caused by the use of the automated translation function.)